Researchers reported camelid-derived “ubi-qubodies” designed to selectively degrade pathogenic mutant CRX proteins, offering a potential therapeutic mechanism for dominant inherited retinal dystrophies. The proof-of-concept work, published in Cell Communication and Signaling, targets mutant CRX variants that appear to escape normal degradation signals. The strategy uses engineered molecules to harness the proteasome, promoting degradation of frame-shift–generated CRX epitopes. The study highlights that about two-thirds of known pathogenic CRX variants stem from frameshift mutations with shared C-terminal architecture, enabling a single targeting approach to cover multiple mutants. In experiments using the p.G122Afs*65 variant, multiple engineered ubiquibodies increased clearance of the mutant protein through proteasome engagement, outperforming clearance observed for wild-type CRX in the same setting. The work is positioned as an adaptable platform concept rather than a single-variant therapy.